NBP Overview

Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

Wall Street analysts forecast NBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBP is8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NovaBridge Biosciences revenue for the last quarter amounts to 0.00 USD, decreased

NovaBridge Biosciences. EPS for the last quarter amounts to -0.12 USD, increased 140.00

NovaBridge Biosciences (NBP) has 30 emplpoyees as of May 11 2026.

Today NBP has the market capitalization of 254.43M USD.